Hydroxychloroquine directly reduces the bindin of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers

Blood

Volumn 112, Issue 5, 2008, Pages 1687-1695

  Rand, Jacob H ^a,e   Wu, Xiao Xuan ^a   Quinn, Anthony S ^b   Chen, Pojen P ^c   Hathcock, James J ^d   Taatjes, Douglas J ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Foreman Pavilion 8 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; GLYCOPROTEIN; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; MULTIPROTEIN COMPLEX; PHOSPHOLIPID;

ACUTE MONOCYTIC LEUKEMIA; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL LEVEL; CONTROLLED STUDY; DRUG INHIBITION; ELLIPSOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; ANTIGEN ANTIBODY COMPLEX; BLOOD; CELL LINE; CHEMISTRY; DRUG EFFECT; IN VITRO STUDY; LIPID BILAYER; METABOLISM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIGEN-ANTIBODY COMPLEX; ANTIMALARIALS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CELL LINE; HUMANS; HYDROXYCHLOROQUINE; LIPID BILAYERS; MICROSCOPY, ATOMIC FORCE; MULTIPROTEIN COMPLEXES; PHOSPHOLIPIDS; PROTEIN BINDING;

EID: 48749104624     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-144204     Document Type: Article

References (45)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria tor definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4: 295-306.
2. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
3. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein l-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104:3598-3602.
4. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res. 2002;90:29-37.
5. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
6. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050-1057.
7. Nayak V, Esdaile JM. The efficacy of antimalarials in systemic lupus erythematosus. Lupus. 1996;5(suppl 1):S23-S27.
8. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: The Canadian Hydroxychloroquine Study Group. Lupus. 1998:7:80-85.
9. Molad Y, Gorshtein A, Wysenbeek AJ, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus: prospective long-term study of an Israeli cohort. Lupus. 2002:11:356-361.
10. Rothfield N. Efficacy of antimalarials in systemic lupus erythematosus. Am J Med. 1988:85:53-56.
11. Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups, XVI: association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473-1480.
12. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Gohort perspective. Scand J Rheumatol. 1996;25:191-193.
13. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002:41:924-929.
14. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospho-lipid antibodies in mice. Circulation. 1997;96: 4380-4384.
15. Espinola RG, Pierangeli SS, GharaAE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human lgG antiphospholipid anti-bodies. Thromb Haemost. 2002;87:518-522.
16. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5(suppl 1):11-15.
17. Willems GM, Janssen MP, Pelsers MM, et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2 glycoprotein I complexes to lipid membranes. Biochemistry. 1996;35:13833-13842.
18. Rand JH, Wu XX, Andree HAM, et al. Antiphos-pholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood. 1998;92:1652-1660.
19. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003:163:1193-1200.
20. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821-824.
21. Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin MD. Phospholipid binding of antiphospholipid antibodies and placental anti-coagulant protein. J Clin Immunol. 1992; 12:27-35.
22. Zhu M, Olee T, Le DT, et al. Characterization of lgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. BrJ Haematol. 1999;105:102-109.
23. Lin WS, Chen PC, Yang CD, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum. 2007;56:1638-1647.
24. Hörkkö S, OleeT, Mo L, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation. 2001;103:941-946.
25. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived lgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost. 2000;84:388-395.
26. Chukwuocha RU, Zhu M, Cho CS, et al. Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. Mol Immunol. 2002;39: 299-311.
27. Rand JH, Wu XX, Giesen P. A possible solution to the paradox of the "lupus anticoagulant": antiphospholipid antibodies accelerate thrombin generation by inhibiting annexin-V. Thromb Haemost. 1999;82:1376-1377.
28. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. " Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol. 1995;154:954-960.
29. Gamsjaeger R, Johs A, Gries A, et al. Membrane binding of beta2-glycoprotein I can be described by a two-state reaction model: an atomic force microscopy and surface plasmon resonance study. Biochem J. 2005;389:665-673.
30. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23:82-91.
31. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95:3460-3466.
32. Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458-459.
33. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771-779.
34. Engen JR, Smithgall TE, Gmeiner WH, Smith DL. Identification and localization of slow, natural, cooperative unfolding in the hematopoietic cell kinase SH3 domain by amide hydrogen exchange and mass spectrometry. Biochemistry. 1997;36: 14384-14391.
35. McCarty GA, Cason TE. Use of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: improvement in antibody titer and symptoms management [abstract]. The 7th International Congress on SLE and related conditions. 2004;Abstract Book, New York:M17A.
36. Erkan D, Derksen WJ, Kaplan V, et al. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis. 2005;64:1321-1325.
37. Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999;18:5166-5174.
38. Schwarzenbacher R, Zeth K. Diederichs K, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18: 6228-6239.
39. Mustard JF, Packham MA. Platelets, thrombosis and drugs. Drugs. 1975;9:19-76.
40. Prowse C, Pepper D, Dawes J. Prevention of the platelet alpha-granule release reaction by membrane-active drugs. Thromb Res. 1982;25: 219-227.
41. Turpie AG. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. Prog Clin Biol Res. 1982;89:31-62.
42. Wolberg AS. Antiphospholipid antibody effects on monocytes. Curr Rheumatol Rep. 2007;9:198-204.
43. Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007;56:2687-2697.
44. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N Engl J Med. 1997;337:154-160.
45. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-853.